Liu Y - Search Results

1

Prospects for miR-21 as a Target in the Treatment of Lung Diseases.

Ding Y, Hou Y, Liu Y, Xie X, Cui Y, Nie H. Ding Y, et al. Among authors: liu y. Curr Pharm Des. 2021;27(3):415-422. doi: 10.2174/1381612826999200820160608. Curr Pharm Des. 2021. PMID: 32867648 Review.

2

Epithelial Barrier Dysfunction Induced by Hypoxia in the Respiratory System.

Hou Y, Ding Y, Liu Y, Xie X, Cui Y, Nie H. Hou Y, et al. Among authors: liu y. Curr Pharm Des. 2020;26(41):5310-5316. doi: 10.2174/1381612826666200825165434. Curr Pharm Des. 2020. PMID: 32842936

3

Regulation of Electrolyte Permeability by Herbal Monomers in Edematous Disorders.

Cui Y, Hou Y, Zhang H, Liu Y, Mao K, Nie H, Ding Y. Cui Y, et al. Among authors: liu y. Curr Pharm Des. 2021;27(6):833-839. doi: 10.2174/1381612826666200917144655. Curr Pharm Des. 2021. PMID: 32940173 Review.

4

MiRNA, a New Treatment Strategy for Pulmonary Fibrosis.

Liu Y, Nie H, Ding Y, Hou Y, Mao K, Cui Y. Liu Y, et al. Curr Drug Targets. 2021;22(7):793-802. doi: 10.2174/1874609813666200928141822. Curr Drug Targets. 2021. PMID: 32988351 Review.

5

Bone marrow mesenchymal stem cells derived miRNA-130b enhances epithelial sodium channel by targeting PTEN.

Zhang H, Ding Y, Hou Y, Liu Y, Zhou Z, Nie H. Zhang H, et al. Among authors: liu y. Respir Res. 2020 Dec 11;21(1):329. doi: 10.1186/s12931-020-01595-7. Respir Res. 2020. PMID: 33308227 Free PMC article.

6

Exosomal MicroRNA: Diagnostic Marker and Therapeutic Tool for Lung Diseases.

Hua Y, Ding Y, Hou Y, Liu Y, Mao K, Cui Y, Nie H. Hua Y, et al. Among authors: liu y. Curr Pharm Des. 2021;27(26):2934-2942. doi: 10.2174/1381612827666210608150640. Curr Pharm Des. 2021. PMID: 34102963

7

Regulation of Cl- Electrolyte Permeability in Epithelia by Active Traditional Chinese Medicine Monomers for Diarrhea.

Chen L, Ding Y, Hou Y, Liu Y, Nie H. Chen L, et al. Among authors: liu y. Curr Drug Targets. 2020;21(9):902-909. doi: 10.2174/1389450121666200504073635. Curr Drug Targets. 2020. PMID: 32364074 Review.

8

The miR-130a-3p/TGF-βRII Axis Participates in Inhibiting the Differentiation of Fibroblasts Induced by TGF-β1.

Liu Y, Ding Y, Hou Y, Yu T, Nie H, Cui Y. Liu Y, et al. Front Pharmacol. 2021 Jul 28;12:732540. doi: 10.3389/fphar.2021.732540. eCollection 2021. Front Pharmacol. 2021. PMID: 34393805 Free PMC article.

9

MiR-130a-3p Alleviates Inflammatory and Fibrotic Phases of Pulmonary Fibrosis Through Proinflammatory Factor TNF-α and Profibrogenic Receptor TGF-βRII.

Ding Y, Hou Y, Liu Y, Yu T, Cui Y, Nie H. Ding Y, et al. Among authors: liu y. Front Pharmacol. 2022 Mar 30;13:863646. doi: 10.3389/fphar.2022.863646. eCollection 2022. Front Pharmacol. 2022. PMID: 35431964 Free PMC article.

10

Experimental studies on the antitumor action of free radicals: antitumor action of galvinoxyl.

Yu LJ, Ding Y, Ma RD, Liu WQ, Duan XZ, Zhang AX, Liu YC, Yang DL, Lei XG, Liu YH. Yu LJ, et al. Among authors: liu wq, liu yc, liu yh. Acta Acad Med Wuhan. 1983;3(1):36-9. doi: 10.1007/BF02858439. Acta Acad Med Wuhan. 1983. PMID: 6866379 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

209,278 results

Search Page

Filters